IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era

: Part B of the modified Magrath regimen (IVAC) +/- rituximab (R) is recommended as standalone therapy by national guidelines for management of relapsed/refractory Burkitt lymphoma, and is used in other non-Hodgkin lymphomas (NHL). Activity of IVAC in B-cell NHL, particularly with R, and its toxicity remain incompletely described.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: Michael J. Buege, Phuong H. Dao, Esther Drill, Andr éa LeVoir, Terry Pak, Tim J. Peterson, David J. Straus Source Type: research